Building a biotechnology startup is a lot like getting a private university education: To make progress, you have to get past the high-cost barrier to entry.
First and foremost, biotech requires expensive clinical studies and the use of state-of-the-art manufacturing facilities. In fact, major pharmaceutical companies spend at least US$4-billion to develop a single drug. That’s not pocket change for the typical entrepreneur. But even biotech startups spend between US$20 000 and US$50 000 per patient on direct clinical trials. And with most Phase II trials requiring at least 200 people for each study, the costs quickly add up.
No ad to show here.
